All In MedTech

Device Trial Radar · NCT05354297

Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions

Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions (ECLIPSE)

Last checked: Nov 20, 2026Latest source record: Jul 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

800

Planned (sponsor's estimate)

Start

Jul 26, 2022

Primary completion

Apr 1, 2023

Study completion Sep 1, 2023

Sponsor

Lead sponsor
LifeScanNot on our public-company list
Sponsor type
Industry
Collaborators
Evidation Health
First posted
Apr 29, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ECLIPSE will evaluate the clinical and economic value of OneTouch Solutions in a real world study design. OneTouch Solutions describes a selection of devices and health and wellness solutions that people with diabetes (PWDs) can access online via OneTouch Solutions (Cecelia Health, Fitbit, Noom or Welldoc, each in combination with OneTouch Verio Reflect® blood glucose meter and the OneTouch Reveal® mobile app (or Welldoc app for the Welldoc arm)). ECLIPSE is a large parallel arm digital health study combining advanced blood glucose monitoring solutions with a choice of four different health and wellness applications or services. There are four unique study arms that will run in parallel over one year. The primary (A1c) endpoint for each study arm will be after 6 months and subjects will continue to use the interventions for a full year to generate data on sustained engagement with these products and services, and to collect healthcare utilization and health insurance claims information. Each study arm will differ to some degree in terms of patient baseline demographics (since subjects self-select their own app/intervention) and the experience per arm will be unique, and therefore each study arm will be analysed separately in terms of endpoints and outcomes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile appDevice

    Expert guidance via coaching

  • Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile appDevice

    Fitness and wellness guidance

  • Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile appDevice

    Behavioral weight loss program

  • Welldoc plus OneTouch Verio Reflect® BGM and Welldoc appDevice

    Multi condition support

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in A1c from screening to 3 and 6 months in each of the OneTouch Solutions programsTime frame: 3 and 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Evidation Health

    San Mateo, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.